Efficient Sensing of a 4-Segmented Rift Valley Fever Virus Vaccine Candidate by Human Monocytes

The Journal of Infectious Diseases 2026 Open access

Read full text
Authors: Niranjana Nair, Julia Friese, Paul J. Wichgers Schreur, Albert D. M. E. Osterhaus, Guus F. Rimmelzwaan, Chittappen Kandiyil Prajeeth
DOI: 10.1093/infdis/jiag085
Cited by: 0
References: 15

Abstract

The live-attenuated RVFV-4s vaccine against Rift Valley fever has demonstrated safety and efficacy across multiple animal models and in a phase 1 clinical trial. In this study, we examined its impact on innate immune responses and found that RVFV-4s enhances the expression of costimulatory molecules critical for T-cell activation, while triggering proinflammatory responses in primary human monocytes.

Fields of Study & Subjects

Viral Infections and Vectors Immunotherapy and Immune Responses Poxvirus research and outbreaks

Publication details

Journal / source
The Journal of Infectious Diseases
Volume
234
Issue
1
Pages
e3–e8
Publication date
10 February 2026
Language
EN